A commentary on “Metabolic tumor burden as a prognostic indicator after neoadjuvant chemotherapy in pancreatic cancer”

aDepartment of Pancreatic Surgery, West China Hospital, Sichuan University, Chengdu, China, 610044 bDepartment of Hepatobiliary Surgery (II), Guizhou Provincial People's Hospital, Guiyang, China, 510002 cDepartment of Breast Surgery, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu, China, 610072 Changyuan Wang and Yi Li equally contributed to the study. Sponsorships or competing interests that may be relevant to content are disclosed at the end of this article. Published online ■ ■ *Corresponding author. Address: E-mail address: [email protected] (B. Tian). This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal. http://creativecommons.org/licenses/by-nc-nd/4.0/